| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $58,697,823 ) (Continued on the next page) |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL158269 | Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | 001 | 4 | NIH | 3/29/2024 | $82,985 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL158269 | Tracing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms | 000 | 4 | NIH | 1/8/2024 | $442,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA241486 | Molecular mechanisms underlying lineage plasticity in prostate cancer | 000 | 5 | NIH | 3/26/2024 | $535,147 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240804 | Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy | 000 | 5 | NIH | 4/1/2024 | $536,452 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240592 | Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer | 000 | 5 | NIH | 1/12/2024 | $309,353 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA245209 | Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | 000 | 5 | NIH | 1/24/2024 | $258,561 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA247375 | CDC7 kinase in normal and cancer cells: potential implications for cancer treatment | 000 | 5 | NIH | 11/13/2023 | $419,566 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA237066 | Targeting of tumor cell DHHC3 to enhance anti-cancer immunity | 000 | 5 | NIH | 2/5/2024 | $360,191 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 6 | NIH | 2/6/2024 | $993,442 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA230503 | Biomarker screening algorithms for the improved early detection of hepatocellular carcinoma | 000 | 6 | NIH | 4/1/2024 | $232,630 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 000 | 1 | NIH | 4/5/2024 | $497,544 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08HD109453 | Identifying metabolic regulation of T cells during early childhood development | 000 | 1 | NIH | 3/21/2024 | $165,240 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA288234 | Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer | 000 | 1 | NIH | 4/8/2024 | $206,067 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 1 | NIH | 1/9/2024 | $735,360 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 1 | NIH | 12/1/2023 | $445,000 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279891 | Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia | 000 | 1 | NIH | 3/25/2024 | $215,179 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 1 | NIH | 1/16/2024 | $505,974 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA286345 | In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity | 000 | 1 | NIH | 1/24/2024 | $268,059 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AI183717 | Symposium on the Immune System of Bacteria | 000 | 1 | NIH | 3/5/2024 | $7,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R61CA278449 | New Chemical Tools for Covalent Drug Discovery | 000 | 1 | NIH | 1/30/2024 | $249,647 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA264296 | Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression | 000 | 3 | NIH | 12/21/2023 | $92,304 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 1 | NIH | 1/19/2024 | $163,728 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 1 | NIH | 3/12/2024 | $721,959 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R03DK138231 | The role of the mesenchymal niche in intestinal crypt fission | 000 | 1 | NIH | 2/7/2024 | $125,700 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 1 | NIH | 12/29/2023 | $728,817 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 001 | 1 | NIH | 4/8/2024 | $0 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 000 | 1 | NIH | 2/15/2024 | $347,254 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 1 | NIH | 2/15/2024 | $736,801 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279414 | A multi-level examination of the influences of racism on cancer pain equity | 000 | 1 | NIH | 2/21/2024 | $775,031 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA279888 | Targeting Menin Protein Stability In AML | 000 | 2 | NIH | 3/12/2024 | $129,600 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 2 | NIH | 1/5/2024 | $628,653 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 2 | NIH | 11/3/2023 | $413,929 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99HG012798 | Robust and cost-effective computational methods for haplotype-resolved genome assemblies | 000 | 2 | NIH | 1/17/2024 | $122,262 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 2 | NIH | 12/21/2023 | $365,314 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269505 | Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation | 000 | 2 | NIH | 3/21/2024 | $460,864 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 2 | NIH | 1/22/2024 | $69,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 000 | 2 | NIH | 12/11/2023 | $240,300 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA267521 | Translation initiation as a therapeutic target in neuroblastoma | 000 | 2 | NIH | 2/8/2024 | $184,499 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA276044 | Liquid biopsy in myeloma to inform outcome and treatment decisions | 000 | 2 | NIH | 1/12/2024 | $366,458 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 000 | 2 | NIH | 2/2/2024 | $505,595 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA277316 | Combined bromodomain and CDK4/6 inhibition in NUT Carcinoma and other solid tumors | 000 | 2 | NIH | 3/25/2024 | $224,889 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 2 | NIH | 11/8/2023 | $127,781 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 3 | NIH | 10/31/2023 | $1,060,855 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00EB030587 | Interrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domains | 000 | 5 | NIH | 2/14/2024 | $211,134 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL157174 | Systematic identification of minor histocompatibility antigens to address GVHD | 000 | 3 | NIH | 3/14/2024 | $664,658 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA259200 | Genomic Diversity of Prostate Cancer Across the African Diaspora | 000 | 3 | NIH | 2/12/2024 | $1,190,653 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 3 | NIH | 1/12/2024 | $612,114 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA245819 | Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage | 000 | 5 | NIH | 12/20/2023 | $93,150 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00AG078230 | Effects of Extracellular Mechanics on Mechanosensory and Central Neuron Function | 000 | 5 | NIH | 1/22/2024 | $93,370 |
|
